GLP-1 drugs continue to transform care for diabetes, obesity and chronic disease, driving new approvals, pricing debates, coverage shifts and evolving health system strategies.Since late 2025, developments in the GLP-1 landscape have unfolded on multiple fronts, from novel formulations and payer policy shifts to access challenges and emerging clinical data.Here’s what you need to know […]
